These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 21696907

  • 1. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.
    Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ, Castanheira M.
    Diagn Microbiol Infect Dis; 2011 Oct; 71(2):167-70. PubMed ID: 21696907
    [Abstract] [Full Text] [Related]

  • 2. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC, Gil J, Ramírez de Ocáriz I, Benito R, Rezusta A.
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [Abstract] [Full Text] [Related]

  • 3. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N, Alem N.
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
    Pfaller MA, Duncanson F, Messer SA, Moet GJ, Jones RN, Castanheira M.
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
    [Abstract] [Full Text] [Related]

  • 5. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K, Pfyffer G, Ruef C, Fehr J, Zbinden R, Calandra T, Bille J, FUNGINOS.
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG.
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [Abstract] [Full Text] [Related]

  • 7. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
    Dagi HT, Findik D, Senkeles C, Arslan U.
    Ann Clin Microbiol Antimicrob; 2016 May 31; 15(1):36. PubMed ID: 27245756
    [Abstract] [Full Text] [Related]

  • 8. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
    Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA.
    Antimicrob Agents Chemother; 2012 Jan 31; 56(1):352-7. PubMed ID: 22083469
    [Abstract] [Full Text] [Related]

  • 9. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.
    Antimicrob Agents Chemother; 2017 Mar 31; 61(3):. PubMed ID: 28052853
    [Abstract] [Full Text] [Related]

  • 10. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC.
    Dan Med J; 2013 Nov 31; 60(11):B4698. PubMed ID: 24192246
    [Abstract] [Full Text] [Related]

  • 11. In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method.
    Eksi F, Gayyurhan ED, Balci I.
    ScientificWorldJournal; 2013 Nov 31; 2013():236903. PubMed ID: 24250260
    [Abstract] [Full Text] [Related]

  • 12. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM, Elizondo M, Ayala J.
    J Clin Microbiol; 2008 Sep 31; 46(9):2902-5. PubMed ID: 18632907
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
    Ozçelik B, Kaynak F, Cesur S, Sipahi B, Sultan N.
    Jpn J Infect Dis; 2007 Sep 31; 60(5):302-4. PubMed ID: 17881873
    [Abstract] [Full Text] [Related]

  • 14. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA.
    J Clin Microbiol; 2006 Feb 31; 44(2):324-6. PubMed ID: 16455878
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
    Miyazaki M, Horii T, Hata K, Watanabe NA, Nakamoto K, Tanaka K, Shirotori S, Murai N, Inoue S, Matsukura M, Abe S, Yoshimatsu K, Asada M.
    Antimicrob Agents Chemother; 2011 Oct 31; 55(10):4652-8. PubMed ID: 21825291
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL, Cheng HH, Lo HJ.
    Int J Antimicrob Agents; 2004 Sep 31; 24(3):294-6. PubMed ID: 15325436
    [Abstract] [Full Text] [Related]

  • 17. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
    Chen TC, Chen YH, Chen YC, Lu PL.
    Kaohsiung J Med Sci; 2012 Jun 31; 28(6):306-15. PubMed ID: 22632885
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
    Pfaller MA, Espinel-Ingroff A, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2011 Mar 31; 49(3):845-50. PubMed ID: 21227994
    [Abstract] [Full Text] [Related]

  • 19. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2005 Nov 31; 43(11):5425-7. PubMed ID: 16272464
    [Abstract] [Full Text] [Related]

  • 20. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
    Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2011 Feb 31; 49(2):630-7. PubMed ID: 21159940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.